Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L, Simon S, Vignard V, Dupre E, Gantier M, Cruard J, Alberge JB, Hussong M, Deleine C, Heslan JM, Shaffer J, Beauvais T, Gaschet J, Scotet E, Fradin D, Jarry A, Nguyen T, Labarriere N. Marotte L, et al. Among authors: alberge jb. J Immunother Cancer. 2020 Jan;8(1):e000311. doi: 10.1136/jitc-2019-000311. J Immunother Cancer. 2020. PMID: 32001504 Free PMC article.
Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study.
Alberge JB, Kraeber-Bodéré F, Jamet B, Touzeau C, Caillon H, Wuilleme S, Béné MC, Kampfenkel T, Sonneveld P, van Duin M, Avet-Loiseau H, Corre J, Magrangeas F, Carlier T, Bodet-Milin C, Chérel M, Moreau P, Minvielle S, Bailly C. Alberge JB, et al. J Nucl Med. 2022 Jul;63(7):1008-1013. doi: 10.2967/jnumed.121.262884. Epub 2022 Jan 27. J Nucl Med. 2022. PMID: 35086897 Free PMC article.
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, Barr H, Murphy C, Sakrikar D, Barnidge D, Bustoros M, Leblebjian H, Cowan A, Davis MI, Amstutz J, Boehner CJ, Lightbody ED, Sklavenitis-Pistofidis R, Perkins MC, Harding S, Mo CC, Kapoor P, Mikhael J, Borrello IM, Fonseca R, Weiss ST, Karlson E, Trippa L, Rebbeck TR, Getz G, Marinac CR, Ghobrial IM. El-Khoury H, et al. Among authors: alberge jb. Lancet Haematol. 2022 May;9(5):e340-e349. doi: 10.1016/S2352-3026(22)00069-2. Epub 2022 Mar 25. Lancet Haematol. 2022. PMID: 35344689 Free PMC article.
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).
Chabrun F, Schwartz D, Gentile S, Mai E, Gupta T, Perry J, Santos DCD, Hielscher T, Werly A, Schmidt S, Theodorakakou F, Fotiou D, Liacos C, Kanellias N, Gisbert N, Martin-Sanchez E, Termini R, Waldschmidt J, Chavda S, Ainley L, Vià MCD, de Magistris C, Pettine L, Timonian M, Alberge JB, Patel V, Costello P, Tobia C, Phan S, Lamb J, Silverio MT, Davis M, O'Donnell E, Marinac C, Nadeem O, Bolli N, Yong K, Kortüm M, Einsele H, Manteca MVM, Kumar S, Miguel JS, Paiva B, Kastritis E, Dimopoulos M, Raab M, Trippa L, Ghobrial I. Chabrun F, et al. Among authors: alberge jb. Res Sq [Preprint]. 2025 Jun 3:rs.3.rs-6696313. doi: 10.21203/rs.3.rs-6696313/v1. Res Sq. 2025. PMID: 40502745 Free PMC article. Preprint.
Genomic landscape of multiple myeloma and its precursor conditions.
Alberge JB, Dutta AK, Poletti A, Coorens THH, Lightbody ED, Toenges R, Loinaz X, Wallin S, Dunford A, Priebe O, Dagan J, Boehner CJ, Horowitz E, Su NK, Barr H, Hevenor L, Towle K, Beesam R, Beckwith JB, Perry J, Cordas Dos Santos DM, Bertamini L, Greipp PT, Kübler K, Arndt PF, Terragna C, Zamagni E, Boyle EM, Yong K, Morgan G, Walker BA, Dimopoulos MA, Kastritis E, Hess J, Sklavenitis-Pistofidis R, Stewart C, Getz G, Ghobrial IM. Alberge JB, et al. Nat Genet. 2025 Jun;57(6):1493-1503. doi: 10.1038/s41588-025-02196-0. Epub 2025 May 21. Nat Genet. 2025. PMID: 40399554 Free PMC article.
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q.
Sklavenitis-Pistofidis R, Lightbody ED, Reidy M, Tsuji J, Alberge JB, Aranha MP, Heilpern-Mallory DL, Roweth HG, Huyng D, Chong SJF, Chung AY, Zhang J, Hackett L, Haradhvala NJ, Wu T, Su NK, Berrios B, Belkin S, Dutta AK, Knudson RA, Brandt C, Greipp PT, Davids MS, Papaioannou M, Getz G, Ghobrial IM, Manier S. Sklavenitis-Pistofidis R, et al. Among authors: alberge jb. Blood. 2025 Mar 12:blood.2024025102. doi: 10.1182/blood.2024025102. Online ahead of print. Blood. 2025. PMID: 40073369
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.
Nadeem O, Aranha MP, Redd R, Timonian M, Magidson S, Lightbody ED, Alberge JB, Bertamini L, Dutta AK, El-Khoury H, Bustoros M, Laubach JP, Bianchi G, O'Donnell E, Wu T, Tsuji J, Anderson KC, Getz G, Trippa L, Richardson PG, Sklavenitis-Pistofidis R, Ghobrial IM. Nadeem O, et al. Among authors: alberge jb. Nat Commun. 2025 Jan 3;16(1):358. doi: 10.1038/s41467-024-55308-5. Nat Commun. 2025. PMID: 39753553 Free PMC article. Clinical Trial.
Serum free light chains in a racially diverse population including African Americans and populations from South Africa.
Bertamini L, Alberge JB, Lee DJ, El-Khoury H, Kim S, Fleming G, Murphy C, Colchie J, Davis MI, Perry J, Lightbody ED, Allam S, Goqwana LN, Philip V, Smyth N, Sakrikar D, Perkins M, Harding S, Troske D, Getz G, Karlson EW, Munshi N, Anderson KC, Trippa L, Marinac CR, Chen WC, Joffe M, Ghobrial IM. Bertamini L, et al. Among authors: alberge jb. Blood. 2025 Feb 20;145(8):840-849. doi: 10.1182/blood.2024026078. Blood. 2025. PMID: 39571144
23 results